|  |  |  |  |
| --- | --- | --- | --- |
|  | **Metastatic (N=34)** | **Non metastatic (N=30)** |  |
| **Variable** | **Mean±SD, Median (Q1-Q3) or N (%)** | **Mean±SD, Median (Q1-Q3) or N (%)** | **p** |
| Age | 54±17.5, 55.8 (44.3-68.7) | 49±21.5, 47.2 (32.2-66.7) | 0.3673 |
| Gender (males) | 21 (61.76%) | 20(66.7%) | 0.7958 |
| Grade (High) | 26(81.25%) | 18/(64.29%) | 0.1569 |
| Molecular Status | Driver oncogenic mechanism: 7 (20.6%) Not known driver oncogenic mechanism: 24 (70.6%) Oncogenesis through virus: 3 (8.8%) | Driver oncogenic  mechanism: 6 (20%) Not known driver oncogenic mechanism: 19 (63.3%) Oncogenesis through virus: 5 (16.7%) | 0.6916 |
| CD45 in LA, n | 0±0.5, 0 (0-1) | 0±0.5, 0 (0-1) | 0.8365 |
| CD45 in LyPS, n | 2±0.9, 2 (1-2.5) | 2±0.9, 1 (1-2) | 0.4250 |
| CD45 in LyIS, n | 2±1, 2 (1-3) | 1±1.1, 1 (0.5-2.5) | 0.2051 |
| CD70 in LA, n | 2±1.5, 2 (0-3) | 1±1.3, 1 (0-3) | 0.4244 |
| CD70 in LyPS, n | 2±1.2, 2 (1-2) | 1±1.1, 1 (0-1) | **0.0107** |
| CD70 in LyIS, n | 1±1.3, 1 (0-2) | 1±1.2, 1 (0-2) | 0.4796 |
| CD70 in tumor cells, n | 2±1.5, 2 (1-3) | 2±1.6, 2 (0-3) | 0.6451 |
| IDO in LA, n | 0±0, 0 (0-0) | 0±0.4, 0 (0-0) | 0.1345 |
| IDO in LyPS, n | 1±0.8, 1 (0-1) | 1±0.9, 1 (0-1) | 0.7438 |
| IDO in LyIS, n | 1±1, 0 (0-1) | 1±1, 0 (0-1) | 0.6222 |
| IDO in tumor cells, n | 0±0, 0 (0-0) | 0±1.2, 0 (0-0) | **0.0149** |
| PD1 in LA, n | 2±1.2, 2 (0-3) | 1±1.4, 2 (0-2) | 0.6664 |
| PD1 in LyPS, n | 1±1, 1 (0-2) | 1±1.1, 0 (0-1) | 0.2538 |
| PD1 in LyIS, n | 1±1.1, 1 (0-2) | 1±1.4, 0 (0-2) | 0.6037 |
| PD1 in tumor cells, n | 0±0.3, 0 (0-0) | 0±0, 0 (0-0) | 0.3570 |
| PD-L1 in LA, n | 1±1.2, 2 (0-2) | 1±1, 0 (0-1) | 0.1571 |
| PD-L1 in LyPS, n | 1±1.1, 0 (0-2) | 0±0.7, 0 (0-0) | 0.1231 |
| PD-L1 in LyIS, n | 1±1, 0 (0-1) | 1±1, 0 (0-1) | 0.5777 |
| PD-L1 in tumor cells, n | 1±1.1, 0 (0-0) | 0±0.9, 0 (0-0) | 0.7234 |
| Death | 20 (58.8%) | 5 (17.2%) | **0.0009** |

**Table S1**